Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2006-04-18
2006-04-18
Wehbe′, Anne Marie S. (Department: 1633)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S227100, C424S189100, C424S085100, C514S002600, C514S04400A
Reexamination Certificate
active
07029680
ABSTRACT:
Compositions of HBsAg particles having biologically active molecules contained in the particles, and methods of their use, e.g. in stimulating enhanced immune responses, are described. Antigenic peptides contained in HBsAg particles were found to produce a CTL response where none was elicited by the peptide alone. Encapsulation of immunostimulating molecules, such as cytokines, greatly enhanced the CTL response evoked by the HBsAg particles themselves.
REFERENCES:
patent: 5039522 (1991-08-01), Neurath
patent: 326109 (1989-02-01), None
patent: 0 326 109 (1989-08-01), None
patent: WO 98/52962 (1998-11-01), None
Yasutomi et al. (1995) J. Virol., vol. 69(4), 2279-2284, 1995.
Fox (1994) Bio/Technology, vol. 12, 128, 1994.
Abbas et al. (1996) Nature, vol. 383, 787-793, 1996.
Golding et al. (1994) Am. J. Trop. Med. Hyg., vol. 50(4), 33-40, 1994.
Michel et. al.; Recombinant hepatitis B surface antigen as a carrier of human immunodefiency virus epitopes, 1993, Institut Pasteur/Elsevier 144: 263-267.
Schirmbeck et al. (1996) Intervirology, vol. 39 (1), 111-119.
Clarke, B.E. et al., “Improved Immunogenicity of a Peptide Epitope after Fusion to Hepatitis B Core Protein,”Nature 330:381 (1987).
Delpeyroux, F. et al., “A Poliovirus Neutralization Epitope Expressed on Hybrid Hepatitis B Surface Antigen Particles,”Science 233:472 (1986).
Diminsky, D. et al., “Comparison Between Hepatitis B Surface Antigen (HBsAg) Particles Derived from Mammalian Cells (CHO) and Yeast Cells (Hansenula polymorpha) : Composition, Structure and Immunogenicity,”Vaccine 15:6/7:637-647 (1997).
Francis, M.J. et al., “Immunological Properties of Hepatitis B Core Antigen Fusion Proteins,”Proc. Natl. Acad. Sci. USA 87:2545-2549 (1990).
Schirmbeck, R. et al., “Immunization with Soluble Hepatitis B Virus Surface Protein Elicits Murine H-2 Class I-Restricted CD8+Cytotoxic T Lymphocyte Responses In Vivo,”J. Immunol. 152(3):1110-1119 (1994).
Davis, H., et al., “CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.” The Journal of Immunology 160(2):870-876(1998).
International Search Report for Application No. PCT/IL99/00060.
Qu, D., et al., “Humoral immune response enhanced by immunization with anti-HBs and HBsAAg complex plus DNA vaccine.” Chem. Abstracts 129(16): 539, abstract No. 201834 (1998).
Qu et al., Humoral immune response enhancer by immunization with anti-HBs and HbsAg complex plus DNA vaccine,Chemical Abstracts, p. 539.
Davis et al., CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant Hepatitis B surface antigen,The Journal of Immunology, 160:870-876 (1998).
Schirmbeck et al., Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T Hymphocytes in nonresponder mice,Journal of Virology, 5929-5934 (1995).
Schirmbeck et al., Enhancing the immunogenicity of exogenous Hepatitis B surface antigen-based vaccines for MHC-O-restricted T cells,Biol. Chem.,380:285-291 (1999).
Puzo, The carbohydrate- and lipid- containing cell wall of mycobacteria, phenolic glycolipids: structure and immunological properties,Microbiology, 17:305-327.
Yamamoto et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length,Antisense Research and Development, 4:119-122 (1994).
Felgner et al., Asymmetric incorporation of trisialoganglioside into dipalmitoylphosphatidylcholine vesicles,Biochemistry, 20:2168-2172 (1981).
Wong et al., Glycolipid transfer protein from bovine brain,Biochemistry, 23:6498-6505 (1984).
Wooldridge et al., Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma,Blood, 89(8):2994-2998 (1997).
Nguyen et al., Constrasting effects of T cell growth factors on T cell responses to melanoma in vitro,Cancer Immunol. Immunother., 43:345-354 (1997).
Weiner et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization,Proc. Natl. Acad. Sci. USA, 94:10833-10837 (1997).
Lowry et al., Protein measurement with the folin phenol reagent,Department of Pharmacology, 265-275 (1951).
Yamamoto et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity,The Journal of Immunology, 148:4072-4076 (1992).
Geissler et al., Enhancement of cellular and humoral immune responses to Hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids,The Journal of Immunology, 1231-1237 (1997).
Yachi et al., Distribution of liposomes containing mannobiose esters of fatty acid in rats,J. Microencapsulation, 12(4)377-388 (1995).
Perin et al., Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate,Nucl. Med. Biol.,21(8)1093-1100 (1994).
Talmon, Transmission electron microscopy of complex fluids: The state of the art,Ber. Bunsenges. Phys. Chem.,100:364-372 (1996).
Delpheyroux et al., A poliovirus neutralization epitope expressed on hybrid Hepatitis B surface antigen particles,Science, 233:472-475 (1986).
Aspinall, “The variable surface glycollpids of mycobacteria: Structures, synthesis of epitopes, and biological properties”,Advances in Carbohydrate Chemistry and Biochemistry, 51:169-243 (1995).
Barenholz Yechezkel
Diminsky Dvorah
Reimann Jörg
Schirmbeck Reinhold
Browdy and Neimark PLLC
Reimann Jorg
Wehbe′ Anne Marie S.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Delivery of immunogenic molecules vis HBsAg particles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery of immunogenic molecules vis HBsAg particles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of immunogenic molecules vis HBsAg particles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586028